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Abstract
Background: The agouti related protein (AGRP) is an endogenous antagonist of the melanocortin
4 receptor and is one of the most potent orexigenic factors. The aim of the present study was to
assess the genetic variability of AGRP gene and investigate whether the previously reported SNP
rs5030980 and the rs11575892, a SNP that so far has not been studied with respect to obesity is
associated with increased body mass index (BMI).
Methods: We determined the complete sequence of the AGRP gene and upstream promoter
region in 95 patients with severe obesity (BMI > 35 kg/m2). Three polymorphisms were identified:
silent mutation c.123G>A (rs34123523) in the second exon, non-synonymous mutation c.199G>A
(rs5030980) and c.131-42C>T (rs11575892) located in the second intron. We further screened
rs11575892 in a selected group of 1135 and rs5030980 in group of 789 participants from the
Genome Database of Latvian Population and Latvian State Research Program Database.
Results: The CT heterozygotes of rs11575892 had significantly higher mean BMI value (p = 0.027).
After adjustment for age, gender and other significant non-genetic factors (presence of diseases),
the BMI levels remained significantly higher in carriers of the rs11575892 T allele (p = 0.001). The
adjusted mean BMI value of CC genotype was 27.92 ± 1.01 kg/m2 (mean, SE) as compared to 30.97
± 1.03 kg/m2 for the CT genotype. No association was found between rs5030980 and BMI.
Conclusion:  This study presents an association of rare allele of AGRP  polymorphism in
heterozygous state with increased BMI. The possible functional effects of this polymorphism are
unclear but may relate to splicing defects.
Background
The central melanocortin system and its components play
an important role in regulation of food intake and energy
balance and it is known as a major pathway of leptin sig-
naling (reviewed in [1,2]). Agouti related protein (AGRP)
is predominantly located in ARC neurons that co-express
neuropeptide Y (NPY), also a strong mediator of regula-
tion of energy balance. AGRP is evolutionary conserved
gene [3] that acts as endogenous melanocortin 4 receptor
(MC4R) and melanocortin 3 receptor (MC3R) antagonist
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(inverse agonist) with strong orexigenic effect (for review
see [4]). Both ICV injection [5,6] and transgenic overex-
pression [7] of AGRP leads to increased food consump-
tion and obesity in mice. Elevated plasma levels of AGRP
have been reported in obese men [8] in comparison to
non-obese men. In addition, AGRP levels are increased in
humans as a result of fasting [9], indicating a possible role
of AGRP in periphery.
The AGRP gene is located on chromosome 16q22, con-
sists of four exons and expresses two alternatively spliced
variants that differ in presence or absence of the 5' non-
coding exon. The long transcript variant is predominantly
expressed in the hypothalamus while the shorter tran-
script lacking the 5' untranslated exon is found in periph-
eral tissues such as testis, lung and kidney [10,11]. A few
single nucleotide polymorphisms (SNPs) have previously
been identified in AGRP  gene that are associated with
energy homeostasis disorder phenotypes. Two SNPs in the
promoter region -3019G>A and -38C>T have been found
in individuals of African origin but not in Caucasians
[12]. Both these SNPs are in complete linkage disequilib-
rium (LD) and are associated with leanness, decreased risk
for type two diabetes (T2DM) and reduced macronutrient
intake [12-14]. Another SNP in the third exon of the AGRP
gene that changes the alanine at position 67 to a threo-
nine (rs5030980) has been identified, and is so far, found
in Caucasians only. This SNP has been shown to be asso-
ciated with anorexia nervosa [15]. Homozygosity of Ala67
did not have any association to a metabolic phenotype at
mean age of 25 years but it was associated with late onset
obesity at mean age of 53 years [16]. Patients homozygous
for the Thr67 allele had significantly reduced body fatness
[17]. In the present study we demonstrate association of a
C>T polymorphism at position c.131-42C>T
(rs11575892) with increased BMI in cohort of patients
from the Latvian Genome Database.
Methods
Study subjects
The study was based on data and samples from the
Genome Database of Latvian Population (Biobank 1), the
disease based biobank comprising 1173 subjects and 439
subjects from population based Latvian State Research
Program Database (Biobank 2). Both biobanks were col-
lected by using the same protocols, questionnaires and
sample treatment techniques. Briefly; individuals were
required to be over the age of 18; the health status was
recorded, the diagnoses was based on approved clinical
criteria according to the ICD-10 codes (International Clas-
sification of Diseases); anthropometric measurements
(including weight and stature), ethnic, social, environ-
mental information and familial health status was
acquired based on self-reported questionnaire. Written
informed consent was obtained from all participants. We
selected 95 of the most obese (BMI > 35 kg/m2) subjects
from the database for initial screening using sequencing.
The study group for the subsequent genotyping of
rs11575892, was selected from all available subjects with
validated health records and questionnaires in biobank by
exclusion of patients with diseases whose outcome or
treatment may influence BMI, including all types of cancer
and diseases of thyroid gland, but not excluding patients
with cardiovascular diseases. Patients with metabolic dis-
eases were included in the study as well. In total 1135 sub-
jects were selected based on these criteria. This sample
group included 73 individuals from the 95 that were
sequenced. rs5030980 was genotyped subsequently in
total of 789 samples comprising 350 samples from
Biobank 1 and all 439 samples included in study from
Biobank 2. The 348 samples from initial selection were
not available for genotyping of rs5030980. Study protocol
was approved by Central Medical Ethics Committee of
Latvia.
Genetic analysis
The AGRP gene containing genomic DNA region includ-
ing 5' upstream region and the entire coding region (posi-
tions from -1102 bp to +1027 respective to start codon)
were amplified in two individual PCRs. Both strands of
amplification products were directly sequenced using set
of six primers (primer sequences and reaction conditions
can be provided upon request from authors). In total 95
overweight individuals (BMI > 35 kg/m2) were sequenced
with 100% success rate. All chromatograms were manu-
ally inspected using Contig Express software of Vector NTI
Advance 9.0 package. Presence of polymorphisms was
confirmed by opposite strand analysis. Restriction
enzyme fragment polymorphism analysis of rs11575892
was used for genotyping the 698 samples from Biobank 1.
Primer with a sequence mismatch in 3' part; 5'-CCCTC-
CCCTGGGAGGTGGG AG-3' (mismatched position
underlined, wild type cuts only) was used to create muta-
tion conditional AluI restriction sites in PCR reaction with
reverse primer; 5'-GGTGAGGGAGTTTGGTGCTGG-3'.
The amplified PCR product contained additional wt AluI
site allowing to control the restriction reaction for false
positive results. The AluI restriction products were visual-
ized on PAAG gels. The samples with polymorphisms
were verified by direct sequencing. Genotyping of the
rs11575892 in all other samples and genotyping of
rs5030980 was performed using pre-designed TaqMan
SNP Genotyping Assays (Applied Biosystems, Foster City,
California, USA) on ABI 7500 Real-Time PCR system
(Applied Biosystems) according to the supplier's recom-
mendations. In addition, the 5' upstream region of the
AGRP sequence for all carriers of the rs11575892 from
Biobank 1 was determined by sequencing. The designa-
tions of the SNP's are based on recommendation by the
Human Genome Variation Society.BMC Medical Genetics 2009, 10:63 http://www.biomedcentral.com/1471-2350/10/63
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Statistical analysis
Statistical analyses were performed with the statistical
package SPSS (Standard Version 12.0.0;SPSS, Chicago, IL,
USA). In contrast to the natural BMI values, the logarith-
mically transformed BMI values displayed normal distri-
bution and were further used for all quantitative analysis.
A one-way ANOVA was used in univariate analysis to test
for association of log-BMI values with other categorical
variables. Linear regression analysis was used to study
relationship between log-BMI and age. General linear
model (GLM) approach was applied to study association
between each SNP and log-BMI adjusting for main effects
of age, gender and those factors that showed association
with logBMI under separate ANOVA tests (presence of
hypertension, angina pectoris, myocardial infarction,
heart failure, dyslipidemia and T2DM). Adjusted mean
logBMI values, corresponding CI intervals and signifi-
cance of association were estimated according to the GLM
model. Logistic regression analysis adjusting for age and
gender was used for dichotomous trait analysis. Power
calculations were performed using Quanto v.1.2.3 [18].
Our sample size provided 80% power (at α = 0.05) to
detect difference between rs11575892 genotypes in log-
BMI of >0.040 assuming minor allele frequency of 0.015
and to detect difference between rs5030980 genotypes in
logBMI of >0.028 assuming minor allele frequency of
0.044. PLINK 1.00 software http://pngu.mgh.har
vard.edu/purcell/plink/[19] was used to perform Hardy-
Weinberg test, LD calculations, haplotype based associa-
tion and permutation test for ANOVA and multivariate
linear regression using label-swapping between SNP and
logBMI values but leaving intact correlation with other
covariates. 100000 permutations were performed for each
analysis and we used corrected (EMP2) p-values. These
values are corrected based on calculation of the propor-
tion of permutations in which any of the test statistics
exceeds the particular observed statistic and are more
stringent then uncorrected p-values.
Results and Discussion
Direct sequencing of the coding and 5' untranslated
regions of the human AGRP gene in 95 obese patients
with BMI > 35 kg/m2  revealed three polymorphisms:
silent mutation c.123G>A (rs34123523) in second exon
(minor allele frequency MAF = 0.042), non-synonymous
mutation c.199G>A (rs5030980) in third exon (MAF =
0.042) and c.131-42C>T (rs11575892) located in second
intron (MAF = 0.016). As reported previously [15]
rs34123523 and rs5030980 were in complete linkage dis-
equilibrium (LD) with each other (D' = 1.00, r2 = 1.00)
while none of these subjects with both SNPs had
rs11575892. The allele frequency of rs5030980 was in
agreement (MAF from 0.036 to 0.05) with previous
reports [13,20]. None of the SNPs currently present in the
SNP databases or any new SNP were found in the 5'
untranslated region of the AGRP gene. The SNPs reported
for this region are however with low frequency (MAF =
0.005 for rs34731556 and rs34018897) or found in sub-
jects of African origin (rs5030981), that may explain the
low number of SNPs in our study.
The rs11575892 had not previously been associated with
any phenotype and we tested the association between this
SNP and BMI in a cohort of 1135 individuals from the
biobank collections that were available to us. Characteris-
tics of the study population for all subjects are presented
in Table 1. The estimated minor allele frequency of
rs11575892 was 0.015 and no significant departure from
Hardy-Weinberg equilibrium was observed (p = 1.0).
When tested for non-genetic factors, we found that hyper-
tension, angina pectoris, heart failure, myocardial infarc-
tion, type 2 diabetes (T2DM) and dyslipidemia were
significantly (p < 0.05) associated with increased logBMI.
We did not find significant difference in logBMI between
females and males (p = 0.34). The results of association
between non-genetic factors and BMI are displayed in
Additional File 1. The age of the patients correlated signif-
icantly with increased BMI (r = 0.204; P < 0.001), when
analyzed using linear regression. In order to remove bias
from confounding factors, we adjusted association of
rs11575892 with BMI using general linear model includ-
ing only those factors and covariate that showed signifi-
cant association with BMI (Table 2). rs11575892 CT
heterozygotes displayed significantly higher (p = 0.001)
mean BMI value compared to the CC genotype (Table 2).
To minimize the false-positive results given the relatively
small sample size and SNP frequency, we repeated the
above mentioned analysis performing permutation test
with 'label swapping' method for both analysis using
exactly the same parameters. Corrected empirical P values
Table 1: Characteristics of the study population.
Variable Number Percentage Mean ± SD
Total number 1135 - -
Females 613 54.0 -
Males 522 46.0 -
Patients with:
Hypertension 375 33.0 -
Angina pectoris 381 33.6 -
Myocardial infarction 246 21.7 -
Heart failure 292 25.7 -
Atrial fibrillation 24 2.1 -
T1DM 53 4.7 -
T2DM 146 12.9 -
dyslipidemia 136 12.0 -
Age (years) 1135 - 56.68 ± 12.52
BMI (kg/m2) 1135 - 28.07 ± 5.36
logBMI 1135 - 1.4407 ± 0.0804
T1DM, type 1 diabetes; T2DM, type 2 diabetes
SD, standard deviation; BMI, body mass indexBMC Medical Genetics 2009, 10:63 http://www.biomedcentral.com/1471-2350/10/63
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generated by permutation test were significant (p =
0.0016) in multivariate linear regression analysis. We also
used median BMI (27.34 kg/m2) as a cut off value for
overweight threshold in a categorical analysis. A signifi-
cant difference in genotype distribution between the nor-
mal and the overweight groups was found in logistic
regression analysis adjusting for age and sex (p = 0.011)
(Table 2).
These results indicate that association of rs11575892 with
increased BMI is not due to possible confounding by spe-
cific diseases or other factors in study cohort. Nevertheless
we cannot completely exclude the role of different envi-
ronmental variables such as social background, diet and
physical activity that could have impact on BMI, but such
parameters were not accessible for present analysis. Due
to low frequency of the rs11575892 polymorphism, we
could only estimate the effect of this genetic variant in its
heterozygous state, as we did not detect any homozygous
individuals who may have pronounced effect of this SNP
on BMI. The power analyses show that the present sample
size had >80% power to detect changes in our logBMI of
0.045. Since rs11575892 has not previously been studied
with respect to obesity and no association for this poly-
morphism has been found with anorexia by Vink et
al[15], further studies with increased sample size or case-
control studies with stratification for environmental fac-
tors such as social background, diet and physical activity
would be valuable to verify the effects of rs1157892. There
are reports that show effects of other AGRP  polymor-
phisms on body weight are expressed in age dependant
fashion [16]. This study group consists mostly of elderly
people (mean 59.0 years) and this could contribute to
enhance the effect of this particular SNP on BMI.
In order to test previously reported associations of
rs5030980 with decreased body fatness we subsequently
performed genotyping in available samples (n = 789) that
were used for genotyping of rs1157892. The estimated
minor allele frequency of rs11575892 was 0.044 and we
did not observe significant departure from Hardy-Wein-
berg equilibrium (p = 1.0). Pairwise LD analysis showed
absence of LD between both SNPs (D' = 1.00, r2 = 0.001).
No association of rs5030980 with BMI was found neither
in GLM or logistic regression analysis (Table 2). We did
not find any difference in mean values between GG and
Table 2: Association of BMI with two SNPs
GLM analysisa
SNP P value
rs11575892 Genotype C/C C/T T/T 0.001
Number 1101 34 -
Mean logBMI ± SE 1.446 ± 0.005 1.491 ± 0.014 -
(95% CI) (1.436–1.456) (1.463–1.518) -
Mean BMIc (kg/m2) 27.92 30.97 -
rs5030980 Genotype G/G G/A A/A 0.986
Number 720 68 1
Mean logBMI ± SE 1.458 ± 0.007 1.458 ± 0.011 1.471 ± 0.076
(95% CI) (1.445–1.472) (1.436–1.481) (1.322–1.620)
Mean BMIc (kg/m2) 28.70 28.70 29.58
Categorical analysis b
SNP Genotype distribution (n) OR (95% CI) P value
BMI <= median BMI > median
rs11575892 C/C 558 543 2.59 (1.24–5.37) 0.011
C/T 12 22
rs5030980 G/G 368 352 1.08 (0.65–1.78) 0.767
G/A 33 35
A/A 0 1
SE, standard error of mean; CI, confidence interval; OR, odds ratio.
a- values from general linear model adjusted for gender, age, presence of hypertension, angina pectoris, myocardial infarction, heart failure and 
T2DM
b- values from logistic regression adjusted for age and gender
c- BMI values back-transformed from mean logBMI valuesBMC Medical Genetics 2009, 10:63 http://www.biomedcentral.com/1471-2350/10/63
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Secondary RNA structure model of AGRP gene fragments containing either C (A) or T (B) at position c.131-42 Figure 1
Secondary RNA structure model of AGRP gene fragments containing either C (A) or T (B) at position c.131-
42. Donor and acceptor sites of second AGRP intron are marked with bold line. Nucleotide positions corresponding to 
rs1157892 are circled. Modeling was done using Mfold program from Vienna RNA package http://www.tbi.univie.ac.at/RNA/.
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GA genotypes as opposite to previous report [16]. We
found only one AA genotype carrier in our study group
with slightly increased BMI value (29.58 kg/m2). This is in
disagreement with results of Marks et.al where carriers of
AA displayed significantly lower BMI [17]. Relatively low
frequency of this SNP however permits to compare these
effects with sufficient power. Haplotype analysis did not
return significant difference in BMI values between three
possible haplotypes (data not shown).
The previously studied SNPs in the promoter region and
the coding sequence of AGRP have been considered to be
functional mutations [21-23], while functional impor-
tance of rs1157892 is unclear. Analysis of secondary RNA
structure models of this region shows significant change
when this SNP is present (see Figure 1) that could influ-
ence a splicing efficiency or promote an alternative splic-
ing. However, if rs1157892 induces production of
truncated or defective AGRP peptide, it would result in
lower stimulation of food intake and lower BMI what is
opposite to the effects found in our study. Our findings
may however be explained by action of the N-terminal
part of AGRP. It has recently been shown that AGRP is
posttranslationally cleaved after Arg82 [24] and it is only
the C-terminal peptide that acts on the melanocortin
receptors. Even though the ICV injection of N-terminal
parts of AGRP (aa25-51) and (aa54-82) did not affect
food consumption in rats, it caused increase of body
weight and epididymal/mesenteric fat weight [25]. It is
therefore possible that rs1157892 may cause splicing
defects resulting in an increased fraction of the N-terminal
AGRP peptide subsequently affecting body weight. Alter-
natively the polymorphism may promote the formation
of more active AGRP isoform as a result of modified splic-
ing reaction. We also performed screening of AGRP gene
sequence for putative gene regulatory factor and micro-
RNA (miRNA) binding sites using online RegRNA soft-
ware (available at http://regrna.mbc.nctu.edu.tw). This
search revealed a sequence that overlaps rs1157892 and is
highly complementary to human miR-330. This comple-
mentarily is significantly decreased in presence of
rs1157892. Even though most of the miRNA functions so
far have been assigned to regulation at mature RNA level
it is shown that miRNA can act in nucleus regulating gene
expression [26]. We can thus speculate that if role of miR-
330 is to suppress AGRP  expression, the presence of
rs1157892 could lead to increase of AGRP synthesis and
subsequent weight gain. It is also possible that rs1157892
may be in linkage disequilibrium with other functional
mutations in regulatory regions of AGRP gene or even in
neighboring genes. It should be noted however that no
polymorphisms where found in the 5' untranslated
region, 1102 bp upstream of AGRP gene neither in carriers
of rs1157892 or other samples included in sequencing.
Conclusion
In summary, our results show novel association of a SNP
in the second intron of AGRP with increased BMI suggest-
ing that naturally occurring mutations in AGRP may be
associated with enhanced effect of this peptide in the
human population. This SNP could provide valuable
information on the regulation of AGRP gene.
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